<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Concept Medical Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=33532></link><description><![CDATA[Concept Medical Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 15 Apr 2026 10:35:46 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2019/08/12_3554238800_20190814152844_9927993555.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1027536</link><description><![CDATA[TAMPA, Fla.--(Business Wire/Korea Newswire)--Concept Medical Inc. , a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first patients in the STARS DAPT (ST-Segment Elevation Myocardial InfArction treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2Y12 inhibitor-based Single Antiplatelet Strategy after a S...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2026/01/1028147215_20260125121420_5414973056.jpg]]></url></image><pubDate>Sun, 25 Jan 2026 13:30:00 +0900</pubDate></item><item><title><![CDATA[컨셉 메디컬, 아블루미너스 엔피 고분자 무함유 DES를 평가하는 STARS DAPT 무작위배정 임상시험 첫 환자 등록 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1027537</link><description><![CDATA[탬파, 플로리다--(Business Wire/뉴스와이어)--컨셉 메디컬(Concept Medical Inc.) 이 혁신적인 약물 전달 기술 분야의 글로벌 선구자로서, 이 STARS DAPT(고분자 무함유 시롤리무스 기반 나노운반체 방출 스텐트 및 짧은 이중 항혈소판 요법 후 P2Y12 억제제 기반 단독 요법 전략 대 기존 이중 항혈소판 요법으로 치료받은 ST 세그먼트 상승 심근경색(ST -Segment Elevation Myocardial Inf A rction treated with a Pol...]]></description><pubDate>Sun, 25 Jan 2026 13:30:00 +0900</pubDate></item><item><title><![CDATA[Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1016177</link><description><![CDATA[TAMPA, Fla.--(Business Wire/Korea Newswire)--Concept Medical Inc. , a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB...]]></description><image><url><![CDATA[https://file.newswire.co.kr/data/datafile2/thumb/2025/08/31017998_20250805151301_3636056832.jpg]]></url></image><pubDate>Tue, 05 Aug 2025 15:50:00 +0900</pubDate></item><item><title><![CDATA[콘셉트 메디컬, MAGICAL-SV IDE 임상시험 첫 환자 등록 발표… 미국 및 유럽으로 관상동맥 임상 프로그램 확대]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1016178</link><description><![CDATA[탬파, 플로리다--(Business Wire/뉴스와이어)--약물 전달 기술 분야의 글로벌 선구자인 콘셉트 메디컬(Concept Medical Inc.) 이 MAGICAL-SV(MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) 임상시험의 첫 환자 등록을 발표했다. 이 시험은 작은 관상동맥 혈관 치료를 위한 자사의 매직터치 SCB(MagicTouch™ sirolimus-coated balloon) 를 평가하기 위해 미국 식품의...]]></description><pubDate>Tue, 05 Aug 2025 15:50:00 +0900</pubDate></item><item><title><![CDATA[콘셉트 메디컬, 시롤리무스 코팅 ‘매직터치’ 제품군에 대한 CE 인증 획득]]></title><link>https://www.newswire.co.kr/newsRead.php?no=895843</link><description><![CDATA[호벨라켄, 네덜란드--(Business Wire/뉴스와이어)--CE 인증 제품과 브랜드는 다음과 같다.   1. 매직터치-PTA(MagicTouch - PTA)(시롤리무스 코팅 PTA 풍선 카테터(Sirolimus Coated PTA Balloon Catheter)): 말초동맥질환용  2. 매직터치-ED(시롤리무스 코팅 풍선 카테터): 발기부전용  3. 매직터치-AVF(MagicTouch - AVF)(시롤리무스 코팅 PTA 풍선 카테터): 동정맥루(Arterio-Venous Fistula) 및 인조혈관용   ‘매직터치-P...]]></description><pubDate>Mon, 21 Oct 2019 10:44:02 +0900</pubDate></item><item><title><![CDATA[Concept Medical is Granted CE Certification for Their Sirolimus Coated MagicTouch Group of Products]]></title><link>https://www.newswire.co.kr/newsRead.php?no=895842</link><description><![CDATA[HOEVELAKEN, The Netherlands--(Business Wire/Korea Newswire)--The CE certified products/brands are as listed below:  1. MagicTouch - PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease 2. MagicTouch - ED (Sirolimus Coated Balloon Catheter) for Erectile Dysfunction 3. MagicTouch - AVF (Sirolimus Coated PTA Balloon Catheter) for Arterio-Venous Fistula and Graft  MagicTouch - PTA is th...]]></description><pubDate>Mon, 21 Oct 2019 10:35:40 +0900</pubDate></item><item><title><![CDATA[콘셉트 메디컬, 매직터치 AVF 시롤리무스 코팅 풍선으로 ‘혁신적 의료기기 지정’ 받아]]></title><link>https://www.newswire.co.kr/newsRead.php?no=893376</link><description><![CDATA[탬파, 플로리다--(Business Wire/뉴스와이어)--콘셉트 메디컬(Concept Medical Inc., ‘CMI’)의 시롤리무스 약물 코팅 풍선(Sirolimus DCB) 카테터인 매직터치 AVF가 미국식품의약국(FDA)으로부터 혁신적 의료기기 지정(Breakthrough Device Designation)을 받았다.  매직터치 AVF는 신부전의 혈액투석 치료에서 동정맥루 혹은 동정맥 이식의 협착성 병변 치료에 사용된다.  FDA는 2019년 7월 매직터치 AVF를 혁신적 의료...]]></description><pubDate>Mon, 02 Sep 2019 11:05:12 +0900</pubDate></item><item><title><![CDATA[Concept Medical Inc. Granted ‘Breakthrough Device Designation’ From the FDA for Its MagicTouch AVF Sirolimus Coated Balloon]]></title><link>https://www.newswire.co.kr/newsRead.php?no=893375</link><description><![CDATA[TAMPA, Fla.--(Business Wire/Korea Newswire)--Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA) for MagicTouch AVF, its Sirolimus drug-coated balloon (DCB) catheter, for the treatment of stenotic lesions of Arteriovenous Fistulae or Arteriovenous graft in hemodialysis treatment of renal failure.  ​​​​​​The FDA rece...]]></description><pubDate>Mon, 02 Sep 2019 10:47:55 +0900</pubDate></item><item><title><![CDATA[콘셉트 메디컬 매직터치 PTA 시롤리무스 약물 코팅 풍선, FDA ‘혁신적 의료기기 지정’ 인정]]></title><link>https://www.newswire.co.kr/newsRead.php?no=892617</link><description><![CDATA[탬파, 플로리다--(Business Wire/뉴스와이어)--콘셉트 메디컬(Concept Medical Inc., CMI)이 미국식품의약국(FDA)으로부터 매직터치 PTA(MagicTouch PTA, Percutaneous Transluminal Angioplasty, 경피경관 혈관성형술)에 대한 혁신적 기기 지정(Breakthrough Device Designation)을 인정받았다고 발표했다.  매직터치 PTA는 하지(Below-the-Knee, BTK) 말초동맥질환(Peripheral Artery Disease, PAD) 치료에 사용되는 시...]]></description><pubDate>Wed, 14 Aug 2019 15:57:47 +0900</pubDate></item><item><title><![CDATA[Concept Medical Granted “Breakthrough Device Designation” by FDA for MagicTouch PTA Sirolimus Coated Balloon]]></title><link>https://www.newswire.co.kr/newsRead.php?no=892616</link><description><![CDATA[TAMPA, Fla.--(Business Wire/Korea Newswire)--Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA (Percutaneous Transluminal Angioplasty), its Sirolimus drug coated balloon (DCB) catheter, for the treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK).  Concept Medical Inc. is backed ...]]></description><pubDate>Wed, 14 Aug 2019 15:37:45 +0900</pubDate></item></channel></rss>